World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
55537
World Ranking
8127
National Ranking
315

G. Kees Hovingh publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where G. Kees Hovingh sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 342 publications — 26th percentile

26% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

G. Kees Hovingh D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where G. Kees Hovingh sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

G. Kees Hovingh is affiliated with the University of Amsterdam in the Netherlands, specializing in medical research with a significant focus on cardiovascular and metabolic health. Their research interests span multiple interconnected fields including surgery, genetics, cardiology and cardiovascular medicine, economics and econometrics, and endocrinology, diabetes, and metabolism.

The scientist's work covers a range of topics primarily related to lipid metabolism and cardiovascular conditions. Key themes in their research include:

  • Lipoproteins and Cardiovascular Health
  • Lipid Metabolism and Disorders
  • Cancer, Lipids, and Metabolism
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Atherosclerosis and Cardiovascular Diseases
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical Economics and Policy

Hovingh has contributed to numerous scientific publications, with a notable presence in specialized journals. The frequent venues for their work include:

  • Atherosclerosis
  • Journal of Clinical Lipidology
  • The Lancet Diabetes & Endocrinology
  • European Journal of Preventive Cardiology
  • Circulation

Some recent representative papers by or involving Hovingh address critical aspects of familial hypercholesterolemia, statin therapy effects, and cardiovascular disease progression. These include:

  • "Long-Term Evolocumab in Patients With Familial Hypercholesterolemia" (2020) published in Journal of the American College of Cardiology
  • "Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia" (2020) published in New England Journal of Medicine
  • "Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis" (2024) published in The Lancet Diabetes & Endocrinology
  • "Marked plaque regression in homozygous familial hypercholesterolemia" (2021) published in Atherosclerosis
  • "Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT" (2022) published in The Lancet Diabetes & Endocrinology

Throughout their career, Hovingh has frequently collaborated with several coauthors, indicating active participation in multi-investigator research projects. Notable frequent coauthors include:

  • Frederick J. Raal
  • Laurens F. Reeskamp
  • Albert Wiegman
  • John J.P. Kastelein
  • Daniel Gaudet

In summary, G. Kees Hovingh's academic contribution centers on medical research with special emphasis on cardiovascular health, lipid disorders, and their systemic metabolic implications, reflected in a consistent output of publications and collaborative research activity.

Best Publications

  • Biological, clinical and population relevance of 95 loci for blood lipids

    Tanya M. Teslovich;Kiran Musunuru;Albert V. Smith;Andrew C. Edmondson

  • Discovery and refinement of loci associated with lipid levels

    Cristen J. Willer;Ellen M. Schmidt;Sebanti Sengupta;Gina M. Peloso;Gina M. Peloso;Gina M. Peloso

  • Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

    Borge G. Nordestgaard;M. John Chapman;Steve E. Humphries;Henry N. Ginsberg

  • Defining the role of common variation in the genomic and biological architecture of adult human height

    Andrew R. Wood;Tonu Esko;Jian Yang;Sailaja Vedantam

  • Large-scale association analysis identifies new risk loci for coronary artery disease

    Panos Deloukas;Stavroula Kanoni;Christina Willenborg;Martin Farrall

  • Genetic studies of body mass index yield new insights for obesity biology

    Adam E. Locke;Bratati Kahali;Sonja I. Berndt;Anne E. Justice

  • Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

    Erik S. Stroes;Paul D. Thompson;Alberto Corsini;Georgirene D. Vladutiu

  • Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

    Marina Cuchel;Eric Bruckert;Henry N. Ginsberg;Frederick J. Raal

  • Common variants associated with plasma triglycerides and risk for coronary artery disease

    Ron Do;Cristen J. Willer;Ellen M. Schmidt;Sebanti Sengupta

  • Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways

    Robert A Scott;Vasiliki Lagou;Ryan P Welch;Eleanor Wheeler

  • Familial Hypercholesterolaemia in Children and Adolescents: Gaining Decades of Life by Optimizing Detection and Treatment

    Albert Wiegman;Samuel S. Gidding;Gerald F Watts;M John Chapman

  • PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2) : a randomised, double-blind, placebo-controlled trial

    Frederick J Raal;Evan A Stein;Robert Dufour;Traci Turner

  • Inhibition of PCSK9 With Evolocumab in Homozygous Familial Hypercholesterolaemia (TESLA Part B): A Randomised, Double-Blind, Placebo-Controlled Trial

    Frederick J Raal;Narimon Honarpour;Dirk J Blom;G Kees Hovingh

  • Measurement of Arterial Wall Thickness as a Surrogate Marker for Atherosclerosis

    Eric de Groot;G. Kees Hovingh;Albert Wiegman;Patrick Duriez

  • Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials

    S. Matthijs Boekholdt;G. Kees Hovingh;Samia Mora;Benoit J. Arsenault

  • HDL and cardiovascular disease

    Daniel J Rader;G Kees Hovingh

  • Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction

    Ron Do;Ron Do;Nathan O. Stitziel;Hong Hee Won;Hong Hee Won;Anders Berg Jørgensen

  • Homozigot ailevi hiperkolesterolemi: klinisyenlerin tanıyı ve klinik yönetimi geliştirmelerine yönelik yeni anlayışlar ve rehberlik. Avrupa Ateroskleroz Derneği’nin Ailevi Hiperkolesterolemi Üzerine Uzlaşı Paneli yazılı görüşü

    Marina Cuchel;Eric Bruckert;Henry N. Ginsberg;Frederick J. Raal

  • ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

    John J.P. Kastelein;Henry N. Ginsberg;Gisle Langslet;G. Kees Hovingh

  • The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

    Robert A. Hegele;Henry N. Ginsberg;M. John Chapman;Børge G. Nordestgaard

Frequent Co-Authors

John J.P. Kastelein
John J.P. Kastelein University of Amsterdam
Nilesh J. Samani
Nilesh J. Samani University of Leicester
Erik S.G. Stroes
Erik S.G. Stroes University of Amsterdam
Nicholas J. Wareham
Nicholas J. Wareham University of Cambridge
Paul W. Franks
Paul W. Franks Lund University
Panos Deloukas
Panos Deloukas Queen Mary University of London
Sekar Kathiresan
Sekar Kathiresan Harvard University
Tonu Esko
Tonu Esko University of Tartu
Markus Perola
Markus Perola Finnish Institute for Health and Welfare
Daniel I. Chasman
Daniel I. Chasman Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Students interested in the medical field have a variety of online degree options and alternative career pathways to consider. Many easy nursing programs to get into are available for those seeking a quicker entry into healthcare, offering less competitive admission requirements while still providing a pathway to licensure.

For those who prefer administrative or behind-the-scenes roles, consider medical billing and coding. You may wonder, can you get financial aid for medical billing and coding? Many accredited online programs do offer financial aid opportunities, making this a more accessible option for career changers or those balancing other commitments.

If you’re interested in starting as a Licensed Practical Nurse (LPN), some programs may not require entrance exams. Learn more: do you have to take a teas test for lpn.

Lastly, leadership positions in healthcare are within reach sooner with expedited online options. Explore the benefits of earning a healthcare administration accelerated degree to start making an impact as a healthcare manager or administrator.

Best Scientists Citing G. Kees Hovingh

Trending Scientists

Recently Published Articles